drugset / Trial / NCT01787331
Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well itraconazole works in treating patients with biochemically relapsed prostate cancer. Itraconazole may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2013-10-29
- Primary completion
- 2017-05-30
- Completion
- 2018-09-30
Publications
- Results Mina Lee, Haemin Hong, Won Kim, Terence W. Friedlander, Lawrence Fong, Amy M. Lin, Eric Jay Small, Mallika Sachdev Dhawan, Xiao X. Wei, Tammy J. Rodvelt, Brigid Miralda, Charles J. Ryan, and Rahul Raj Aggarwal.A phase II study of itraconazole in biochemically recurrent prostate cancer. Journal of Clinical Oncology 2018 36:6_suppl, 362-362
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Itraconazole | Small molecule | 300 mg | Oral |